AU2023367530A1 - Pharmaceutical composition for treating and/or preventing renal cystic ciliopathy - Google Patents

Pharmaceutical composition for treating and/or preventing renal cystic ciliopathy Download PDF

Info

Publication number
AU2023367530A1
AU2023367530A1 AU2023367530A AU2023367530A AU2023367530A1 AU 2023367530 A1 AU2023367530 A1 AU 2023367530A1 AU 2023367530 A AU2023367530 A AU 2023367530A AU 2023367530 A AU2023367530 A AU 2023367530A AU 2023367530 A1 AU2023367530 A1 AU 2023367530A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
ttnpb
pharmaceutically acceptable
ciliopathy
cystic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023367530A
Other languages
English (en)
Inventor
Fumihiko HATTANDA
Shinichi MAE
Saori NISHIO
Kenji Osafune
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hokkaido University NUC
Kyoto University NUC
Original Assignee
Hokkaido University NUC
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hokkaido University NUC, Kyoto University NUC filed Critical Hokkaido University NUC
Publication of AU2023367530A1 publication Critical patent/AU2023367530A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023367530A 2022-10-26 2023-10-26 Pharmaceutical composition for treating and/or preventing renal cystic ciliopathy Pending AU2023367530A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022-171387 2022-10-26
JP2022171387 2022-10-26
PCT/JP2023/038716 WO2024090521A1 (ja) 2022-10-26 2023-10-26 腎嚢胞性繊毛病の治療及び／又は予防のための医薬組成物

Publications (1)

Publication Number Publication Date
AU2023367530A1 true AU2023367530A1 (en) 2025-03-27

Family

ID=90830957

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023367530A Pending AU2023367530A1 (en) 2022-10-26 2023-10-26 Pharmaceutical composition for treating and/or preventing renal cystic ciliopathy

Country Status (7)

Country Link
US (2) US12514834B2 (https=)
EP (1) EP4574171A4 (https=)
JP (1) JP7619587B2 (https=)
KR (1) KR20250089512A (https=)
CN (1) CN120091831A (https=)
AU (1) AU2023367530A1 (https=)
WO (1) WO2024090521A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7837529B1 (ja) * 2024-11-06 2026-03-31 国立大学法人京都大学 常染色体顕性（優性）多発性嚢胞腎治療用医薬組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3633026A4 (en) 2017-05-25 2021-03-10 Kyoto University METHOD FOR INDUCING THE DIFFERENTIATION OF A MESODERMAL INTERMEDIATE CELL TO A KIDNEY PRECURSOR CELL AND METHOD FOR INDUCING THE DIFFERENTIATION OF A PLURIPOTENT STEM CELL FROM A KIDNEY PRECURSOR CELL
JP2022180668A (ja) 2019-10-17 2022-12-07 学校法人杏林学園 腎機能障害の治療剤
US20240010989A1 (en) 2021-01-08 2024-01-11 Kyoto University Medium for culturing and expanding nephron progenitor cells, method for culturing and expanding nephron progenitor cells, and method for producing renal organoids
WO2022210968A1 (ja) 2021-03-31 2022-10-06 国立大学法人京都大学 嚢胞構造を有する人工集合管オルガノイド

Also Published As

Publication number Publication date
JPWO2024090521A1 (https=) 2024-05-02
EP4574171A4 (en) 2025-12-24
JP7619587B2 (ja) 2025-01-22
KR20250089512A (ko) 2025-06-18
US12514834B2 (en) 2026-01-06
US20260053763A1 (en) 2026-02-26
CN120091831A (zh) 2025-06-03
EP4574171A1 (en) 2025-06-25
WO2024090521A1 (ja) 2024-05-02
US20250170083A1 (en) 2025-05-29

Similar Documents

Publication Publication Date Title
US20240390427A1 (en) Methods and compositions relating to chondrisomes from cultured cells
Thabet et al. Extracellular vesicles miRNA-21: a potential therapeutic tool in premature ovarian dysfunction
Li et al. Human umbilical cord mesenchymal stem cell-derived exosomes improve ovarian function in natural aging by inhibiting apoptosis
US20260053763A1 (en) Pharmaceutical composition for treating and/or preventing renal cystic ciliopathy
JP5950428B2 (ja) 線維化組織から正常組織を再生するための組成物
WO2018226230A1 (en) Compounds and methods for treatment of diamond blackfan anemia
Lu et al. CPEB2-activated axonal translation of VGLUT2 mRNA promotes glutamatergic transmission and presynaptic plasticity
Remen et al. The liver X receptor promotes macrophage differentiation and suppresses osteoclast formation in mouse RAW264. 7 promyelocytic leukemia cells exposed to bacterial lipopolysaccharide
JP2019089726A (ja) がん遺伝子産物ｙａｐ１／ｔａｚ機能調節剤
Wei et al. Neurofibromin 1 controls metabolic balance and Notch-dependent quiescence of murine juvenile myogenic progenitors
Kamel et al. Morpholino-mediated knockdown in primary chondrocytes implicates Hoxc8 in regulation of cell cycle progression
JP6023824B2 (ja) 線維化組織から正常組織を再生するための組成物
Costigan Investigating the Role of Mitochondrial Metabolism in Human Kidney Development and Maldevelopment
Alotaiq Cavin-1-mediated regulation of suppressor of cytokine signalling 3 (SOCS3) function
Zhang et al. METTL3-Mediated m6A Modification is Involved in Neural Tube Defects via Modulating Wnt/β-Catenin Signaling Pathway
Ferguson The Spatial and Temporal Role of EZH2 in Skull Bone Formation
Tu et al. Physiological Notch Signaling Maintains Bone Homeostasis via RBPjk and Hey Upstream of
Di Canio Regulation of oligodendrocyte lineage cell function by the RXR𝛾 nuclear receptor Ludovica Di Canio Department of Clinical Neurosciences
Němcová Molecular mechanisms of apoptosis regulation by fatty acids in pancreatic β-cells